- Research article
- Open Access
- Open Peer Review
Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects
© Choi et al; licensee BioMed Central Ltd. 2009
- Received: 18 March 2009
- Accepted: 16 September 2009
- Published: 16 September 2009
Although much progress has been made on antipsychotic drug development, precise mechanisms behind the action of typical and atypical antipsychotics are poorly understood.
We performed genome-wide expression profiling to study effects of typical antipsychotics and atypical antipsychotics in the postmortem liver of schizophrenia patients using microarrays (Affymetrix U133 plus2.0). We classified the subjects into typical antipsychotics (n = 24) or atypical antipsychotics (n = 26) based on their medication history, and compared gene expression profiles with unaffected controls (n = 34). We further analyzed individual antipsychotic effects on gene expression by sub-classifying the subjects into four major antipsychotic groups including haloperidol, phenothiazines, olanzapine and risperidone.
Typical antipsychotics affected genes associated with nuclear protein, stress responses and phosphorylation, whereas atypical antipsychotics affected genes associated with golgi/endoplasmic reticulum and cytoplasm transport. Comparison between typical antipsychotics and atypical antipsychotics further identified genes associated with lipid metabolism and mitochondrial function. Analyses on individual antipsychotics revealed a set of genes (151 transcripts, FDR adjusted p < 0.05) that are differentially regulated by four antipsychotics, particularly by phenothiazines, in the liver of schizophrenia patients.
Typical antipsychotics and atypical antipsychotics affect different genes and biological function in the liver. Typical antipsychotic phenothiazines exert robust effects on gene expression in the liver that may lead to liver toxicity. The genes found in the current study may benefit antipsychotic drug development with better therapeutic and side effect profiles.
- Atypical Antipsychotic
- Schizophrenia Patient
Differential therapeutic and side effects of typical antipsychotic (AP) and atypical AP drugs in schizophrenia have been documented [1, 2]. Typical APs such as haloperidol and phenothiazines induce elevation of serum prolactin, extrapyramidal symptoms and tardive dyskinesia, whereas atypical APs such as clozapine and olanzapine induce metabolic syndromes and elevation of liver enzyme levels [3–6]. However, precise mechanisms underlying the effects of typical and atypical AP drugs on gene expression in the postmortem liver of schizophrenia patients are poorly understood. Unlike typical APs, atypical APs appear to increase liver enzyme function although they induce less hepatotoxicity [7–9]. The atypical AP drug clozapine induces a metabolic syndrome by down-regulating cytochrome P450 (CYP450) isozymes and by causing an accumulation of fatty acids in the liver . However, certain typical APs, including chlorpromazine and haloperidol, may also decrease the activity of CYP450 isozymes in the liver of rats [11, 12]. While the effects of APs on liver function have been confirmed in individuals with schizophrenia, additional pharmacological and clinical factors could also contribute to altered liver function . Interestingly, a study suggested that the metabolic alterations leading to oxidative stress in the liver of schizophrenia patients may actually be linked to the disease process itself .
Previous postmortem brain studies identified gene expression changes in metabolism-related pathways in schizophrenia [15, 16]. However, other studies found that AP medication may act to compensate for the underlying pathological deficits in the metabolic pathways in schizophrenia [17, 18]. For instance, genes involved in lipid metabolism and cellular signaling are altered in the mice brains by chronic AP treatment , suggesting that the metabolic abnormalities may also be a function of the AP medication. In schizophrenia, abnormal myelination and oligodendrocytes have been described  and both typical and atypical APs may regulate the expression of genes associated with lipid biosynthesis and myelination in cultured human glioma cells . Interestingly, these genes are controlled by the sterol regulatory element-binding protein (SREBP) transcription factors. Thus, SREBP-mediated increase in glial cell lipogenesis could be one of the potential mechanisms behind the AP medication. Also, genes associated with cell cycle, intracellular signaling, oxidative stress and metabolic functions are altered in the lymphocytes of schizophrenia patients compared to normal controls . However, this study identified the schizophrenia subjects as medicated, minimally medicated and un-medicated, so that it is difficult to interpret which AP class affected those genes. In the human liver tissues, typical APs and atypical APs may mediate different functions leading to liver toxicity in schizophrenia patients who had taken typical APs . However, atypical AP treatment may increase levels of liver enzymes such as alanine aminotransfeaminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and alkaline phosphotase (ALP) . Taken together, these studies suggest that typical APs may cause liver toxicity whereas atypical APs may regulate liver enzyme functions. To our knowledge, the effects of different APs on genome-wide expression profiles in the postmortem liver of schizophrenia patients have not been reported.
Given the various effects of APs on genes and biological functions in different tissues, we investigated the effects of typical APs and atypical APs on gene expression profiles in the postmortem liver of schizophrenia patients. We classified the schizophrenia subjects into either typical AP group or atypical AP group based on their medication history from one or two years prior to death, and compared gene expression profiles with unaffected controls. We further analyzed individual AP medication effects on gene expression by sub-classifying the subjects into four major AP drug groups including phenothiazines, haloperidol, olanzapine and risperidone.
Postmortem liver tissues
Postmortem liver tissues were obtained from the Stanley Medical Research Institute (SMRI). The details of the postmortem tissue collection have been described previously . Information on medication was taken from the clinical and the medical records, reviewed in each case. The postmortem tissues were collected between 1995 and 2005 during the period when the use of typical AP medication was decreasing and the use of atypical AP medication was increasing. Thus, individual patients at the time of death were being treated with typical or atypical AP drugs. For quality of the tissue, exclusion criteria included: age>65 years, poor quality RNA, and significant structural pathology of the liver on postmortem examination. Samples were matched for age, gender, race, pH and total RNA quality. Total RNA quality was determined by the Bioanalyzer 2100 electrophoresis system (Agilent Technologies, Foster City, CA, USA) using RNA Integrity Number (RIN) as previously described . The schizophrenia subjects were classified into two groups: those who had taken predominantly typical APs (phenothiazines, thioxanthenes, butyrophenones, and diphenylbutylpiperidines) and those who had taken predominantly atypical APs (clozapine, risperidone, olanzapine, quetiapine, and aripiprazole). The brain collection protocol was reviewed and approved by the SMRI. Detailed information on ethical approval can be found at http://www.stanleyresearch.org.
Frozen postmortem liver tissue was homogenized in Trizol (Invitrogen, Carlsbad, CA), and the RNA was separated with chloroform and high-speed centrifugation. RNA was precipitated with isopropyl alcohol and washed with 70% ethanol and the pellets of RNA were resuspended in DEPC water . An additional step of RNeasy column purification (Qiagen, Valencia, CA) was added to increase the efficiency of RNA quantification and purity. A genome-wide expression microarray experiment was carried out using the Affymetrix chips (HG-U133 plus2.0, 54,675 transcripts) at the Microarray Core Facility of the Johns Hopkins University (Baltimore, MD). Microarray data including cel files, normalized data and demographic information can be found at the Stanley Online Genomics Database (https://www.stanleygenomics.org, Study id: 19).
Quality control of microarrays
The Affymetrix Microarray Analysis Suite 5.0 (MAS 5.0) expression values were calculated based on scaling to a target intensity of 100, then transformed by log2 (x+20). Absent/Present calls were computed using the MAS 5.0 algorithm. The Absent/Present call rate was used for gene filtering prior to the data analysis. All analysis was conducted using the R statistical environment (R Development Core Team (2007). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria). For the quality control (QC) analysis, several primary QC metrics were used including: scale factor, percent present, number of probes with perfect match>mis-match, 5'/3' GAPDH, 5'/3' Actin and average correlation. For each metric, we computed the distribution of the metric across the samples within each study. Although no hard cutoffs were applied for each of the QC metrics, we examined the distribution of the metrics to determine whether samples appeared to be outliers as described previously [26–29].
Demographic and clinical variable analyses
Each demographic and clinical variable was assessed using regression analysis. The percentage of regulated probes in each variable was calculated based on the criteria of significance (p < 0.001 and fold change >1.3). For the comparison of effect sizes, all demographics were analyzed using two levels. Continuous variables and ordered categorical variables were cut at median values for the regression analysis. Demographic factors were assessed using all samples including those from the unaffected controls, and the typical and atypical AP groups. Schizophrenia-specific variables were analyzed only in schizophrenia cases to avoid the confounding of demographic effects and disease effects. The following demographic and clinical variables were considered for all subjects: age, gender, postmortem interval (PMI), body mass index (BMI), pH, mRNA quality, heavy alcohol use, heavy drug use and rate of death. The following clinical variables were considered for the subjects with schizophrenia: global severity of disease, suicide status, exacerbation of disease at the time of death, insight, and duration of illness. Global severity of disease is an estimate of the severity of illness for the entire course of illness. All schizophrenia patients were rated against others. This assessment includes both symptom severity and social disability. Exacerbation of disease is an estimate of whether the person's symptoms were getting worse at the time of death. Heavy drug and alcohol use reflect substance abuse in the past and at time of death. Insight is an assessment of the individual's awareness of his/her illness. The assessment is based on the medical records or from the family about whether the individual voluntarily sought treatment and complied with medication.
Antipsychotic medication analysis
Demographic and clinical variable analyses revealed several confounding variables affecting expression of a significant number of genes in the liver (refrigerator time, PMI, rate of death, RNA quality, heavy drug use, heavy alcohol use, gender and suicide). Therefore, these confounding variables were adjusted for AP class analysis in a series of linear regression models, one model for each gene, including typical or atypical AP drugs and eight confounding variables as covariates and gene expression intensity (log2 scale) as the dependent variable. The criteria of significance for each gene were FC >1.3 and p < 0.001 after adjusting for the confounding variables.
Following the AP class comparisons, individual AP drug effects on gene expression in the liver were investigated. Based on the recent medication history (one or two years prior to death), the subjects were sub-classified into four individual AP drug groups including phenothiazines (n = 12), haloperidol (n = 9), olanzapine (n = 11) and risperidone (n = 10). Schizophrenia subjects (n = 8) who had taken both typical and atypical AP drugs during this period were excluded. Individual AP drug comparisons were performed using a single factor ANOVA to identify genes that are differentially expressed among the AP drug groups (FDR adjusted p < 0.05). The results from individual AP drug analysis were compared with the results from AP class comparisons (multiple regression analyses) to identify common set of genes between the two analyses.
The NCBI's Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov) was used as the standard source for gene annotation information . In the DAVID annotation system, the Fisher's Exact test was used to measure the gene-enrichment in annotation terms. The primary fields extracted from the DAVID include Entrez Gene ID, gene symbol and gene summary. Additional annotations included gene product mappings to the Gene Ontology Consortium (GO) for GO terms.
Total RNA was extracted from the postmortem liver tissue, and the quality of RNA was assessed with the Bioanalyzer 2100 (Agilent, Foster City, CA). RNA was further purified with the PureLink Micro to Midi Total RNA Purification System (Invitrogen, Carlsbad, CA), and cDNA was synthesized with RT-PCR using oligo dT primers. Using a 384-well format with the ABI Prism 7900HT real-time detector, 1 μl aliquots of QuantiTect SYBR primer (20×), 10 μl QPCR PCR Master mix (Applied Biosystems, Foster City, CA), and 10 μl diluted cDNA were mixed together and pipetted into single wells of the qPCR plate. Water was added instead of cDNA in the no template controls (NTC) for each gene tested. Thermo cycle conditions were: (1) 1 cycle for 2 min at 50°C, (2) 1 cycle for 15 min at 95°C, and (3) 40 cycles for 15 sec at 95°C and 1 min at 60°C and fluorescence was measured during the 60°C step for each cycle as recommended by the manufacturer. Target genes include ATP-binding cassette, sub-family G, member 5 (ABCG5, NM_022436, QT00023415), androgen receptor 1 (AR1, NM_005650, QT00076615), CCAAT/enhancer binding protein, alpha (CEBPA, (NM_004364, QT00203357), cytochrome P450, family 51, subfamily A, polypeptide 1 (CYP51A1, NM_000786, QT00055790), cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1, NM_000780, QT00001085), FOS-like antigen 2 (FOSL2, NM_005253, QT01000881), interleukin 1 receptor antagonist (IL1RN, NM_173843, QT01002918) and superoxide dismutase 2 (SOD2, NM_000636, QT01008693). Three endogenous control genes were selected for the qPCR experiment: β-2 microglobulin (B2M, NM_004048, QT00088935), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_002046, QT01192646) and β-actin (ACTB, NM_001101, QT00095431). Polymerase chain reactions were quantified by the relative ΔΔCt method using the SDS2.2 software (Applied Biosystems, Foster City, CA). An average Ct value for each sample from the triplicates of that sample was calculated for each gene. Geometric mean of three endogenous control genes (B2M, ACTB and GAPDH) was used to normalize the data for each gene of interest. The normalized values for each gene of interest in the typical AP class were expressed as fold change (FC) as compared to the atypical AP class.
A summary of subject characteristics.
No. of Subjects
45.9 ± 1.8
47.1 ± 2.2
42.8 ± 2.4
6.4 ± 0.1
6.4 ± 0.1
6.5 ± 0.1
27.2 ± 2.5
36.3 ± 3.7
37.1 ± 4.7
29.2 ± 1.5
29.6 ± 1.3
30.5 ± 1.5
Heavy Drug Use
Heavy Alcohol Use
A summary of fold changes and p-values for the transcripts (p < 0.01) in comparison between the typical AP vs. the controls, the atypical AP vs. the controls, and the typical AP vs. the atypical AP.
T vs. AT
T vs. AT
T vs. AT
1.5 - 2
Significant biological terms in each comparison between typical AP vs. control, atypical AP vs. control, and typical AP vs. atypical AP.
Typical vs. Ctrl
Typical vs. Ctrl
Response to stress
Typical vs. Ctrl
Typical vs. Ctrl
Basic-leucine zipper (bZIP) transcription factor
Typical vs. Ctrl
Atypical vs. Ctrl
Atypical vs. Ctrl
Atypical vs. Ctrl
ER to Golgi vesicle-mediated transport
Atypical vs. Ctrl
Atypical vs. Ctrl
Golgi vesicle transport
Typical vs. Atypical
Cellular lipid metabolism
Typical vs. Atypical
Typical vs. Atypical
Typical vs. Atypical
Intracellular membrane-bound organelle
Typical vs. Atypical
It is well accepted that typical APs and atypical APs mediate differential therapeutic and side effects in individuals who are taking AP medications. Most previous studies have focused on the effects of typical APs and atypical APs on gene expression and on drug metabolism using animal models. Recent studies have investigated the effects of the APs in the postmortem brains using gene expression microarrays [33, 34]. However, to our knowledge, none has reported the effects of APs on global gene expression profiles in the postmortem liver of schizophrenia patients. Based on the previous studies on liver function, it is likely that atypical APs have fewer side effects and less liver toxicity than typical APs [35, 36] and these differences may be partially due to the differential gene expression pattern induced by two different classes of AP drugs.
Effects of typical antipsychotics on gene expression
We found that typical APs affected the genes associated with nuclear protein, response to stress and phosphorylation in the liver (Table 3). The genes associated with nuclear protein include many transcription factors and DNA binding proteins that are crucial to regulating expression of other genes in the nucleus of cells. The typical AP haloperidol has been shown to induce DNA methylation changes in the brain and peripheral tissue of rats . Another typical APs phenothiazines may contribute to liver toxicity , extrapyramidal side effects  and chromosomal DNA damage . Thus, these studies suggest that typical APs may regulate biological functions related to nuclear protein and stress responses in the liver of schizophrenia patients.
Effects of atypical antipsychotics on gene expression
In contrast, atypical APs affected genes associated with the golgi apparatus/endoplasmic reticulum in the liver. The genes associated with this category were consistently up-regulated, suggesting that atypical APs may regulate transport mechanisms in the cytoplasm rather than affecting gene expression cascades in the nucleus of cells. We found that the genes associated with cytoplasmic function are up-regulated in the atypical AP group (Additional file 5). Previous animal studies reported that chronic administration of atypical APs, in contrast to typical APs, does not cause toxic effects in the liver . However, the atypical AP clozapine does induce a metabolic syndrome including weight gain, glucose tolerance and insulin sensitivity via alteration of glucose metabolism in rats . Our results suggest that there are clear differences between the typical APs and the atypical APs on gene expression profiles in the liver of schizophrenia patients, consistent with the previous animal studies [19, 42].
Comparison between typical antipsychotics and atypical antipsychotics
Comparison between the typical APs and the atypical APs revealed that genes associated with lipid metabolism and biosynthesis are differentially regulated. Two CYP450 isozyme genes, CYP51A1 and CYP7A1, were down-regulated and these changes were confirmed by the qPCR. Although previous studies reported the significance of CYP450 systems in AP drug metabolism, the role of these two isozymes have not been reported. The significance of the metabolic syndrome in schizophrenia, particularly the potential side effects of atypical APs on lipid metabolism, has been described previously [43, 44]. For example, the typical AP drug haloperidol reduced expression of CYP450 genes in the liver of rats . Many APs are metabolized by the CYP450 isozymes and also the enzyme activities are also regulated by the APs [46, 47]. Therefore, a subset of CYP450 isozymes may have different responses to typical APs or atypical APs in the liver of schizophrenia patients.
Another biological function between the typical APs and the atypical APs was mitochondrial function with 11 genes down-regulated and 3 genes up-regulated (Additional file 6). A study reported mitochondrial dysfunction in schizophrenia  and mitochondrial genes may also be affected by AP medication. For example, the APs induced changes in mitochondria-related genes in postmortem brains of schizophrenia . The authors suggested that this was a medication effect rather than the disease itself because the brains of AP-free schizophrenia cases did not show similar effects on the mitochondrial genes. Moreover, typical and atypical AP drugs exert different effects on mitochondrial function in the rat liver and these differences may provide a possible link to extrapyramidal symptoms observed in patients taking typical APs . The typical AP, thioridazine, also interacts with the inner membrane of mitochondria, acquiring antioxidant activity toward processes with potential implications in apoptosis . Taken together, these results suggest that APs affect the genes associated with mitochondrial function in the brain and in the liver.
There were 20 genes common between two comparisons (typical AP vs. control and atypical AP vs. control) based on the significance criteria (FC>1.3 and p < 0.001). These genes include enzymes such as transglutaminase 2 (TGM2), nicotinamide N-methyltransferase (NNMT), and inositol(myo)-1(or 4)-monophosphatase 2 (IMPA2). Therefore, these enzymes may be involved in common metabolic pathways affected by both typical AP and atypical AP classes in the liver of schizophrenia patients. Although we only investigated gene expression profiles in the liver, it is possible that these genes may be affected by both typical APs and atypical APs in other tissues. Since both typical AP and atypical AP drugs improve positive symptoms of schizophrenia , the common genes found between two comparisons may provide clues to similar therapeutic and side effect profiles.
Effects of individual antipsychotic drugs on gene expression
Based on individual AP drug comparisons, we identified 158 transcripts that are differentially expressed among four AP drugs (FDR adjusted p < 0.05). Among the four AP drugs compared, the phenothiazines affected most of the genes, and a subset of those genes (n = 26) were associated with stress responses (adjusted p = 0.001, fold enrichment = 3.21). This indicates that phenothiazines (chlorpromazine, fluphenazine and thioridazine) with similar chemical structure produce robust effects on gene expression that could contribute to liver toxicity , extrapyramidal side effects  and even chromosomal DNA damage  observed with phenothiazines. For instance, we found that expression of C-reactive protein (CRP), a marker of inflammation, was dramatically increased by the phenothiazines (FC 21, FDR-adjusted p = 0.0002). This corroborates a recent study that reported serum CRP levels are increased more in schizophrenia patients who had taken typical APs as compared to those who had taken atypical APs . This also suggests that the phenothiazines affect the immune system and may cause oxidative stress in the peripheral tissues.
Quantitative PCR has become a standard for validating gene expression changes identified in microarray studies [53, 54]. We selected a set of genes differentially expressed between the typical AP and the atypical AP classes, and validated the gene expression using qPCR. The CCAAT/enhancer binding protein alpha (CEBPA) gene encodes a basic leucine zipper motif (bZIP) transcription factor that binds to the promoter and modulates the expression of the leptin gene, a protein that plays an important role in body weight homeostasis. The typical AP chlorpromazine has been shown to increase insulin sensitivity in the liver by attenuating insulin and leptin signaling pathways . It is interesting that one of the main side effects of atypical APs is weight gain and dysfunction of the CEBPA gene may contribute to this side effect. The ATP-binding cassette (ABCG5) gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes and are expressed in liver tissue. Polymorphisms in the ABC gene are associated with treatment resistance in schizophrenia and response to the atypical AP drug risperidone in schizophrenia [56, 57]. These studies suggest that the ABC genes may play a role in responses to different APs in schizophrenia.
Among the up-regulated genes, FOS-like antigen 2 (FOSL2) encodes leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. Chronic treatment with APs induces long-lasting expression of the FOS and JUN family genes and AP-1 complex in the rat prefrontal cortex . Although APs have been shown to regulate the expression of FOS and JUN family genes in the rat brain [58–60], the effect of typical APs and atypical APs on these genes in the liver have not been reported. The superoxide dismutase 2 (SOD2) gene encodes a mitochondrial protein that forms a homotetramer and binds one manganese ion per subunit. The functions of the SOD2 protein include binding to the superoxide byproducts of oxidative phosphorylation and converting them to hydrogen peroxide and diatomic oxygen. While chronic administration of the typical AP chlorpromazine decreases SOD enzyme activity in the brain and in erythrocytes , the effects in the liver are not known. The interleukin 1 receptor antagonist (IL1RN) gene inhibits the activities of interleukin 1, and modulates a variety of interleukin 1-related immune and inflammatory responses. Genes associated with the immune and inflammatory responses have been reported in schizophrenia [62, 63]. Functional polymorphisms in the interleukin genes have been reported in schizophrenia  and therefore, interleukin genes may be promising candidates for research in schizophrenia.
Strength of the current study
It is well known that gene expression studies using postmortem tissues of psychiatric patients are challenging [65–68]. Disease-specific effects are often hindered by issues such as relatively small sample size, small effect size and heterogeneity of symptoms in the patient population . Also, clinical information available on each patient is often incomplete, and so unknown clinical covariates may either confound or confuse many of the gene expression findings [26, 28]. Therefore, appropriate statistical adjustment using available information is critical in order to improve inferences in determining candidate genes and the biology behind psychiatric disorders. However, most previous studies have not accounted for these issues or made adequate adjustments using appropriate statistical methods. In this study, we first analyzed the demographic and clinical variables, in order to identify potential confounding effects on gene expression. We then performed the multiple regression analyses to adjust the confounding variables on a gene-by-gene level to obtain adjusted p-values and fold changes for the analysis of AP medication effects.
Previous studies reported that gene expression fold changes between unaffected controls and psychiatric patients are relatively small, and statistical significance is relatively weak, especially after adjusting for multiple confounding variables . Compared to the postmortem brain tissues, we found that the gene expression changes are quite robust in the postmortem liver tissues. This may be due to the direct and profound effects of APs on gene expression in the liver as compared to the confounding medication and disease effects found in the brain. Also, the robust effects observed in the liver may be due to the cell-type homogeneity of the liver compared to the brain, in which several cell types are present in any given region.
Although the current study investigated the effects of AP medications on gene expression profiles in the postmortem liver of schizophrenia patients, caution is required when interpreting the results. Clinical information available from each patient is often incomplete and AP medication effects are confounded by heterogeneous medication regimen. For instance, some patients had a mixed medication history with prescriptions for both typical and atypical AP drugs during the course of the illness. However, the current analysis revealed that the typical AP class, not the atypical AP class, exerts robust gene expression changes in the liver of schizophrenia patients. In order to address individual AP drug effects on gene expression, we sub-classified the schizophrenia subjects into 4 AP groups based on their recent medication history from one or two years prior to death. Although it was not possible to obtain complete medication history and information on medication adherence from each patient, we attempted to identify genes and biological functions that are affected by those four AP drugs including phenothiazines, haloperidol, olanzapine and risperidone in the liver. Due to the limitations inherent to the postmortem tissues of psychiatric patients, the current study should be considered as exploratory rather than conclusive. Further animal and cell culture studies with controlled medication regimen are necessary to extend the findings from the current study.
Typical AP and atypical AP medication affect different genes and biological functions in the liver of schizophrenia patients. The typical AP phenothiazines produced robust effects on gene expression and a subset of those genes are associated with stress responses in the liver. Thus, the genes and the pathways identified in the current study may provide important clues to the differential therapeutic and side effects mediated by two different classes of APs. Moreover, the current findings may provide useful information for developing novel APs with better therapeutic and side effect profiles.
We thank Mr. Suad Diglisic for helping experiment and Dr. E Fuller Torrey for invaluable discussion on the manuscript. This work was supported by the SMRI.
- Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, et al: Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006, 86 (1-3): 234-243. 10.1016/j.schres.2006.06.021.View ArticlePubMedGoogle Scholar
- Bender S, Grohmann R, Engel RR, Degner D, Dittmann-Balcar A, Ruther E: Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry. 2004, 37 (Suppl 1): S46-53.PubMedGoogle Scholar
- Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A: Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30 (6): 1163-1166. 10.1016/j.pnpbp.2006.03.014.View ArticlePubMedGoogle Scholar
- Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH: Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol. 2005, 20 (3): 173-176. 10.1097/00004850-200505000-00009.View ArticlePubMedGoogle Scholar
- Gaertner I, Altendorf K, Batra A, Gaertner HJ: Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001, 21 (2): 215-222. 10.1097/00004714-200104000-00014.View ArticlePubMedGoogle Scholar
- Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002, 47 (1): 27-38.PubMedGoogle Scholar
- Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y: A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31 (6): 1255-1260. 10.1016/j.pnpbp.2007.05.005.View ArticlePubMedGoogle Scholar
- Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW: Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997, 17 (4): 314-317. 10.1097/00004714-199708000-00012.View ArticlePubMedGoogle Scholar
- Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR: The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 1994, 18 (3): 537-544. 10.1016/0278-5846(94)90010-8.View ArticlePubMedGoogle Scholar
- Zhang WV, Ramzan I, Murray M: Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther. 2007, 322 (2): 770-777. 10.1124/jpet.107.124024.View ArticlePubMedGoogle Scholar
- Haduch A, Wojcikowski J, Daniel WA: Direct effects of neuroleptics on the activity of CYP2A in the liver of rats. Pharmacol Rep. 2005, 57 (6): 867-871.PubMedGoogle Scholar
- Haduch A, Ogorka T, Boksa J, Daniel WA: Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. Pharmacol Rep. 2005, 57 (6): 872-877.PubMedGoogle Scholar
- Garcia-Unzueta MT, Herran A, Sierra-Biddle D, Amado JA, Vazquez-Barquero JL, Alvarez C: Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal. 2003, 17 (6): 216-218. 10.1002/jcla.10094.View ArticlePubMedGoogle Scholar
- Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S: 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res. 2007, 6 (1): 141-149. 10.1021/pr060308a.View ArticlePubMedGoogle Scholar
- Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S: Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol. 2007, 10 (4): 557-563. 10.1017/S1461145706007334.View ArticlePubMedGoogle Scholar
- Vawter MP, Shannon Weickert C, Ferran E, Matsumoto M, Overman K, Hyde TM, Weinberger DR, Bunney WE, Kleinman JE: Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res. 2004, 29 (6): 1245-1255. 10.1023/B:NERE.0000023611.99452.47.View ArticlePubMedGoogle Scholar
- Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P: Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 2002, 22 (7): 2718-2729.PubMedGoogle Scholar
- Thomas EA: Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders. Mol Neurobiol. 2006, 34 (2): 109-128. 10.1385/MN:34:2:109.View ArticlePubMedGoogle Scholar
- Mehler-Wex C, Grunblatt E, Zeiske S, Gille G, Rausch D, Warnke A, Gerlach M: Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J Neural Transm. 2006, 113 (10): 1383-1393. 10.1007/s00702-005-0425-y.View ArticlePubMedGoogle Scholar
- Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V: Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res. 2006, 85 (1-3): 245-253. 10.1016/j.schres.2006.03.029.View ArticlePubMedGoogle Scholar
- Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, et al: Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J. 2005, 5 (5): 298-304. 10.1038/sj.tpj.6500323.View ArticlePubMedGoogle Scholar
- Craddock RM, Lockstone HE, Rider DA, Wayland MT, Harris LJ, McKenna PJ, Bahn S: Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS ONE. 2007, 2 (1): e692-10.1371/journal.pone.0000692.View ArticlePubMedPubMed CentralGoogle Scholar
- Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D: [Hepatic tolerance of atypical antipsychotic drugs]. Encephale. 2002, 28 (6 Pt 1): 542-551.PubMedGoogle Scholar
- Torrey EF, Webster M, Knable M, Johnston N, Yolken RH: The stanley foundation brain collection and neuropathology consortium. Schizophr Res. 2000, 44 (2): 151-155. 10.1016/S0920-9964(99)00192-9.View ArticlePubMedGoogle Scholar
- Weis S, Llenos IC, Dulay JR, Elashoff M, Martinez-Murillo F, Miller CL: Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology. J Neurosci Methods. 2007, 165 (2): 198-209. 10.1016/j.jneumeth.2007.06.001.View ArticlePubMedGoogle Scholar
- Higgs BW, Elashoff M, Richman S, Barci B: An online database for brain disease research. BMC Genomics. 2006, 7: 70-10.1186/1471-2164-7-70.View ArticlePubMedPubMed CentralGoogle Scholar
- Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, Barci BM, Torrey EF: Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci. 2007, 31 (3): 221-243.PubMedGoogle Scholar
- Choi KH, Elashoff M, Higgs BW, Song J, Kim S, Sabunciyan S, Diglisic S, Yolken RH, Knable MB, Torrey EF, et al: Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry. 2008, 8: 87-10.1186/1471-244X-8-87.View ArticlePubMedPubMed CentralGoogle Scholar
- Elashoff M: Role of statistics in toxicogenomics. Methods Mol Biol. 2008, 460: 69-87.View ArticlePubMedGoogle Scholar
- Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4 (5): P3-10.1186/gb-2003-4-5-p3.View ArticlePubMedGoogle Scholar
- Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P, Pearce DA, Singh S, Siderovski DP, Willard FS, et al: Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology. 2006, 31 (9): 1888-1899. 10.1038/sj.npp.1301002.View ArticlePubMedGoogle Scholar
- Feher LZ, Kalman J, Puskas LG, Gyulveszi G, Kitajka K, Penke B, Palotas M, Samarova EI, Molnar J, Zvara A, et al: Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem Int. 2005, 47 (4): 271-280. 10.1016/j.neuint.2005.04.020.View ArticlePubMedGoogle Scholar
- Arion D, Unger T, Lewis DA, Levitt P, Mirnics K: Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2007, 62 (7): 711-721. 10.1016/j.biopsych.2006.12.021.View ArticlePubMedPubMed CentralGoogle Scholar
- Prasad KM, Chowdari KV, Nimgaonkar VL, Talkowski ME, Lewis DA, Keshavan MS: Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Mol Psychiatry. 2005, 10 (2): 213-219. 10.1038/sj.mp.4001562.View ArticlePubMedGoogle Scholar
- Kinross-Wright V, Moyer JH: Chlorpromazine and Hepatic Function. AMA Archives of Neurology and Psychiatry. 1956, 675-680.Google Scholar
- Bartholomew LG, Cain JC, Frazier SH, Petersen MC, Foulk WT, Soule EH, Fleisher GA, Owen CA: Effect of chlorpromazine on the liver. Gastroenterology. 1958, 34 (6): 1096-1107.PubMedGoogle Scholar
- Shimabukuro M, Jinno Y, Fuke C, Okazaki Y: Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats. Behav Brain Funct. 2006, 2: 37-10.1186/1744-9081-2-37.View ArticlePubMedPubMed CentralGoogle Scholar
- Peacock L, Solgaard T, Lublin H, Gerlach J: Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl). 1996, 124 (1-2): 188-196. 10.1007/BF02245620.View ArticleGoogle Scholar
- Madle S, Obe G, Schroeter H, Herha J, Pietzcker A: Possible mutagenicity of the psychoactive phenothiazine derivative perazine in vivo and in vitro. Hum Genet. 1980, 53 (3): 357-361. 10.1007/BF00287056.View ArticlePubMedGoogle Scholar
- Halici Z, Keles ON, Unal D, Albayrak M, Suleyman H, Cadirci E, Unal B, Kaplan S: Chronically Administered Risperidone Did Not Change the Number of Hepatocytes in Rats: A Stereological and Histopathological Study. Basic Clin Pharmacol Toxicol. 2008, 102 (5): 426-32. 10.1111/j.1742-7843.2007.00198.x.View ArticlePubMedGoogle Scholar
- Tulipano G, Rizzetti C, Bianchi I, Fanzani A, Spano P, Cocchi D: Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology. 2007, 85 (2): 61-70. 10.1159/000100981.View ArticlePubMedGoogle Scholar
- Pillai A, Parikh V, Terry AV, Mahadik SP: Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res. 2007, 41 (5): 372-386. 10.1016/j.jpsychires.2006.01.011.View ArticlePubMedGoogle Scholar
- Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19 (Suppl 1): 1-93.PubMedGoogle Scholar
- Newcomer JW: Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007, 68 (Suppl 4): 8-13.PubMedGoogle Scholar
- Hanagama M, Inoue H, Kamiya M, Shinone K, Nata M: Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. Leg Med (Tokyo). 2008, 10 (4): 177-84.View ArticleGoogle Scholar
- Wojcikowski J, Pichard-Garcia L, Maurel P, Daniel WA: The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004, 14 (3): 199-208. 10.1016/S0924-977X(03)00105-6.View ArticlePubMedGoogle Scholar
- Wojcikowski J, Maurel P, Daniel WA: Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos. 2006, 34 (3): 471-476.PubMedGoogle Scholar
- Ben-Shachar D: Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem. 2002, 83 (6): 1241-1251. 10.1046/j.1471-4159.2002.01263.x.View ArticlePubMedGoogle Scholar
- Iwamoto K, Bundo M, Kato T: Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005, 14 (2): 241-253. 10.1093/hmg/ddi022.View ArticlePubMedGoogle Scholar
- Modica-Napolitano JS, Lagace CJ, Brennan WA, Aprille JR: Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch Pharm Res. 2003, 26 (11): 951-959. 10.1007/BF02980205.View ArticlePubMedGoogle Scholar
- Rodrigues T, Santos AC, Pigoso AA, Mingatto FE, Uyemura SA, Curti C: Thioridazine interacts with the membrane of mitochondria acquiring antioxidant activity toward apoptosis--potentially implicated mechanisms. Br J Pharmacol. 2002, 136 (1): 136-142. 10.1038/sj.bjp.0704672.View ArticlePubMedPubMed CentralGoogle Scholar
- Carrizo E, Fernandez V, Quintero J, Connell L, Rodriguez Z, Mosquera M, Acosta A, Baptista T: Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res. 2008, 103 (1-3): 83-93. 10.1016/j.schres.2008.03.004.View ArticlePubMedGoogle Scholar
- Mimmack ML, Brooking J, Bahn S: Quantitative polymerase chain reaction: validation of microarray results from postmortem brain studies. Biol Psychiatry. 2004, 55 (4): 337-345. 10.1016/j.biopsych.2003.09.007.View ArticlePubMedGoogle Scholar
- Miller CL, Diglisic S, Leister F, Webster M, Yolken RH: Evaluating RNA status for RT-PCR in extracts of postmortem human brain tissue. Biotechniques. 2004, 36 (4): 628-633.PubMedGoogle Scholar
- Park S, Hong SM, Lee JE, Sung SR: Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects. Life Sci. 2007, 80 (26): 2428-2435. 10.1016/j.lfs.2007.04.001.View ArticlePubMedGoogle Scholar
- Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, Meng J, Zhang A, Qin S, He L: Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006, 7 (7): 987-993. 10.2217/146224188.8.131.527.View ArticlePubMedGoogle Scholar
- Takao T, Tachikawa H, Kawanishi Y, Katano T, Sen B, Homma M, Kohda Y, Mizukami K, Asada T: Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr Genet. 2006, 16 (2): 47-48. 10.1097/01.ypg.0000194441.04684.db.View ArticlePubMedGoogle Scholar
- Kontkanen O, Lakso M, Wong G, Castren E: Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology. 2002, 27 (2): 152-162. 10.1016/S0893-133X(02)00289-0.View ArticlePubMedGoogle Scholar
- Rodriguez JJ, Garcia DR, Nakabeppu Y, Pickel VM: Enhancement of laminar FosB expression in frontal cortex of rats receiving long chronic clozapine administration. Exp Neurol. 2001, 168 (2): 392-401. 10.1006/exnr.2000.7612.View ArticlePubMedGoogle Scholar
- MacGibbon GA, Lawlor PA, Bravo R, Dragunow M: Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res. 1994, 23 (1-2): 21-32. 10.1016/0169-328X(94)90207-0.View ArticlePubMedGoogle Scholar
- Abdalla DS, Bechara EJ: The effect of chlorpromazine and Li2CO3 on the superoxide dismutase and glutathione peroxidase activities of rat brain, liver and erythrocytes. Biochem Mol Biol Int. 1994, 34 (6): 1085-1090.PubMedGoogle Scholar
- Shao L, Vawter MP: Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry. 2008, 64 (2): 89-97. 10.1016/j.biopsych.2007.11.010.View ArticlePubMedPubMed CentralGoogle Scholar
- Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E: Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry. 2007, 7: 46-10.1186/1471-244X-7-46.View ArticlePubMedPubMed CentralGoogle Scholar
- Schwarz MJ, Kronig H, Riedel M, Dehning S, Douhet A, Spellmann I, Ackenheil M, Moller HJ, Muller N: IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2006, 256 (2): 72-76. 10.1007/s00406-005-0603-9.View ArticlePubMedGoogle Scholar
- Iwamoto K, Kato T: Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist. 2006, 12 (4): 349-361. 10.1177/1073858406287536.View ArticlePubMedGoogle Scholar
- Miklos GL, Maleszka R: Microarray reality checks in the context of a complex disease. Nat Biotechnol. 2004, 22 (5): 615-621. 10.1038/nbt965.View ArticlePubMedGoogle Scholar
- Mirnics K, Levitt P, Lewis DA: Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry. 2006, 60 (2): 163-176. 10.1016/j.biopsych.2006.02.003.View ArticlePubMedGoogle Scholar
- Bahn S, Augood SJ, Ryan M, Standaert DG, Starkey M, Emson PC: Gene expression profiling in the post-mortem human brain--no cause for dismay. J Chem Neuroanat. 2001, 22 (1-2): 79-94. 10.1016/S0891-0618(01)00099-0.View ArticlePubMedGoogle Scholar
- Ryan MM, Huffaker SJ, Webster MJ, Wayland M, Freeman T, Bahn S: Application and optimization of microarray technologies for human postmortem brain studies. Biol Psychiatry. 2004, 55 (4): 329-336. 10.1016/j.biopsych.2003.10.016.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/9/57/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.